Innovent Biologics, Inc.

Innovent Biologics, Inc.verified

IVBXF

Price:

$4.5682

Market Cap:

$7.47B

Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarci...[Read more]

Industry

Biotechnology

IPO Date

2019-09-04

Stock Exchange

PNK

Ticker

IVBXF

The Enterprise Value as of November 2024 (TTM) for Innovent Biologics, Inc. (IVBXF) is 8.35B

According to Innovent Biologics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 8.35B. This represents a change of -78.21% compared to the average of 38.30B of the last 4 quarters.

Innovent Biologics, Inc. (IVBXF) Historical Enterprise Value (quarterly & annually)

How has IVBXF Enterprise Value performed in the past?

The mean historical Enterprise Value of Innovent Biologics, Inc. over the last ten years is 40.88B. The current 8.35B Enterprise Value has changed 1.94% with respect to the historical average. Over the past ten years (40 quarters), IVBXF's Enterprise Value was at its highest in in the June 2021 quarter at 108.82B. The Enterprise Value was at its lowest in in the March 2021 quarter at -9322770000.00.

Quarterly (TTM)
Annual

Average

40.88B

Median

36.28B

Minimum

3.53B

Maximum

90.69B

Innovent Biologics, Inc. (IVBXF) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Innovent Biologics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 646.49%

Maximum Annual Enterprise Value = 90.69B

Minimum Annual Increase = -84.64%

Minimum Annual Enterprise Value = 3.53B

Quarterly (TTM)
Annual
YearEnterprise ValueChange
202355.34B19.64%
202246.25B-20.26%
202158.00B-36.04%
202090.69B244.63%
201926.31B646.49%
20183.53B-84.64%
201722.95B-4.29%

Innovent Biologics, Inc. (IVBXF) Average Enterprise Value

How has IVBXF Enterprise Value performed in the past?

The current Enterprise Value of Innovent Biologics, Inc. (IVBXF) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

53.20B

5-year avg

55.32B

10-year avg

40.88B

Innovent Biologics, Inc. (IVBXF) Enterprise Value vs. Peers

How is IVBXF’s Enterprise Value compared to its peers?

Innovent Biologics, Inc.’s Enterprise Value is greater than Telix Pharmaceuticals Limited (6.70B), greater than Keros Therapeutics, Inc. (1.86B), greater than MAIA Biotechnology, Inc. (57.27M), greater than Graphite Bio, Inc. (-15007658.00), less than Genscript Biotech Corporation (0), greater than Oxford Nanopore Technologies plc (3.70B), greater than Nuvalent, Inc. (1.20B), greater than Crinetics Pharmaceuticals, Inc. (6.17B), greater than Inhibrx Biosciences, Inc. (4.87B), greater than Merus N.V. (411.31K), greater than Lyell Immunopharma, Inc. (3.08B), greater than Kronos Bio, Inc. (251.92M), greater than Theseus Pharmaceuticals, Inc. (14.20M), greater than Cullinan Oncology, Inc. (138.26M), greater than Mersana Therapeutics, Inc. (810.70M), greater than Relay Therapeutics, Inc. (199.03M), greater than Arcus Biosciences, Inc. (867.37M), greater than null (1.28B),

Build a custom stock screener for Innovent Biologics, Inc. (IVBXF) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Innovent Biologics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Innovent Biologics, Inc. (IVBXF) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Innovent Biologics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Innovent Biologics, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Innovent Biologics, Inc. (IVBXF)?

What is the 3-year average Enterprise Value for Innovent Biologics, Inc. (IVBXF)?

What is the 5-year average Enterprise Value for Innovent Biologics, Inc. (IVBXF)?

How does the current Enterprise Value for Innovent Biologics, Inc. (IVBXF) compare to its historical average?